Expenditure and Prescriptions twelve months to 30 June 2015
Page last updated: 4 May 2016
Tables of prescription volumes and government costs (expenditures) under the Pharmaceutical Benefits Scheme.
The same document broken into smaller sections:
- Summary of PBS Processing year ending 30 June 2015
- Table 1(a) Pharmaceutical Benefits Expenditure on accrual accounting basis (PDF 9 KB) - (Excel 197 KB, Tables 1-20)
- Table 1(b) PBS Section 85 Prescription Volume and Government Cost (PDF 9 KB) - (Excel 197 KB, Tables 1-20)
- Table 1(c) RPBS Section 85 Prescription Volume and Government Cost (PDF 9 KB) - (Excel 197 KB, Tables 1-20)
- Table 2 PBS Prescription Volume, Government Cost and Patient Contributions Table (PDF 9 KB) - (Excel 197 KB, Tables 1-20)
- Table 2(a) PBS Prescription Volume and Government Cost by monthly summary (excl. Drs Bag) (PDF 9 KB) - (Excel 197 KB, Tables 1-20)
- Table 3 PBS Processing by State (excl Drs Bag) (PDF 8 KB) - (Excel 197 KB, Tables 1-20)
- Table 4(a) PBS Processing (excl Drs Bag) Table (PDF 8 KB) - (Excel 197 KB, Tables 1-20)
- Table 4(b) PBS Processing (incl Drs Bag), Highest Cost/Volume Drug and ATC 2 Group (PDF 8 KB) - (Excel 197 KB, Tables 1-20)
- Table 5 ATC Main Group Comparison (incl Drs Bag) (PDF 9 KB) - (Excel 197 KB, Tables 1-20)
- Table 6 PBS Prescription Volume, Government Cost & Average Government Cost/Script (excl. Drs Bag) (PDF 8 KB) - (Excel 197 KB, Tables 1-20)
- Table 7(a) Significant Drugs (incl Drs Bag) by Highest Government Cost (PDF 11 KB) - (Excel 197 KB, Tables 1-20)
- Table 7(b) Significant Drugs (incl Drs Bag) by Highest Volume (PDF 11 KB) - (Excel 197 KB, Tables 1-20)
- Table 8(a) Significant Drugs (incl Drs Bag) sorted by Highest Change to Government Cost (PDF 11 KB) - (Excel 197 KB, Tables 1-20)
- Table 8(b) Significant Drugs (incl Drs Bag) sorted by Highest Volume Change (PDF 11 KB) (Excel 197 KB, Tables 1-20)
- Table 9(a) Highest Government Cost PBS Drugs (incl Drs Bag) by Generic Name (PDF 9 KB) - (Excel 197 KB, Tables 1-20)
- Table 9(b) Highest Volume PBS Drugs (incl Drs Bag) by Generic Name (PDF 9 KB) - (Excel 197 KB, Tables 1-20)
- Table 10(a) Highest Government Cost Drug (incl Drs Bag) by PBS Item (PDF 14 KB) - (Excel 197 KB, Tables 1-20)
- Table 10(b) Highest Volume Drug (incl Drs Bag) by PBS Item (PDF 12 KB) - (Excel 197 KB, Tables 1-20)
- Table 11 Highest volume (incl under co-payment scripts) PBS Drugs (incl Drs Bag) by ATC Group Level 2 (PDF 9 KB) - (Excel 197 KB, Tables 1-20)
- Table 12 Highest volume (incl under co-payment scripts) PBS Drugs (incl Drs Bag) by Generic name (PDF 8 KB) - (Excel 197 KB, Tables 1-20)
- Table 13 Highest volume (incl under co-payment scripts) PBS Drugs (incl Drs Bag) by PBS Item (PDF 11 KB) - (Excel 197 KB, Tables 1-20)
- Table 14 PBS processing by Formulary (excl. Drs Bag) (PDF 7KB) - (Excel 197 KB, Tables 1-20)
- Table 15(a) Top 20 Responsible Persons by Total Cost (PDF 10 KB) - (Excel 197 KB, Tables 1-20)
- Table 15(b) Top 20 Responsible Persons by Market Share (Scripts) (PDF 10 KB) - (Excel 197 KB, Tables 1-20)
- Table 16 PBS Other - Summary of direct payments and advances (PDF 8 KB) - (Excel 197 KB, Tables 1-20)
Supplement 1
- Table 17(a) Safety Net Card Issues, Persons Covered (PDF 10 KB) - (Excel 197 KB, Tables 1-20)
- Table 17(b) Safety Net Card Issues, Number of Cards (PDF 8 KB) - (Excel 197 KB, Tables 1-20)
- Table 18 Pharmacies and Friendly Societies (PDF 11 KB) - (Excel 197 KB, Tables 1-20)
- Table 19 Special Patient Contributions (PDF 7 KB) - (Excel 197 KB, Tables 1-20)
- Table 20(a) Pharmaceutical Benefits Scheme, Prescriptions - History (PDF 13 KB) - (Excel 197 KB, Tables 1-20)
- Table 20(b) Pharmaceutical Benefits Scheme, Government Cost - History (PDF 24 KB) - (Excel 197 KB, Tables 1-20)
Supplement 2
Supplement 3
- National Diabetes Services Scheme (NDSS) (PDF 33 KB) - (Word 24 KB)
- National Diabetes Services Scheme Chart (NDSS) (PDF 33 KB) - (Excel 45 KB)
Supplement 4
Summary of Pharmaceutical Benefits processing, year ending 30 June 2015
Government Pharmaceutical Benefits expenditure on accrual accounting basis for the year ending 30 June 2015 totalled $9,072.1 million, compared with $9,148.5 million for the previous year. This is a 0.8 per cent decrease. The remainder of this summary refers to Pharmaceutical Benefits Scheme (PBS) Section 85 data reported on cash accounting basis.
Total PBS prescription volumes increased by 0.8 per cent to a total of 211.4 million, compared to 209.8 million for the previous year.
Government expenditure amounted to 82.7 per cent of the total cost of PBS prescriptions. The remainder was patient contributions that amounted to $1,484.6 million, down from $1,545.1 million in the previous twelve-month period.
The majority of government expenditure on PBS prescriptions was directed towards concessional cardholders ($5,486.2 million, 77.4% of the total). This is compared to concessional expenditure of $5,708.0 million in the previous period (78.1% of the total).
The average dispensed price per prescription of PBS medicines decreased to $40.52 for the year ending June 2015 ($42.20 for the year ending June 2014). The average government cost of these scripts was $33.48 for the same period ($34.82 to June 2014).
The three drugs with the highest cost to government were Adalimumab ($313.0 million), Rosuvastatin ($215.9 million) and Fluticasone+Salmeterol ($177.2 million). The PBS drugs most frequently dispensed were Atorvastatin, followed by Rosuvastatin and Esomeprazole. See Table 9(b) for details.
Important Information
Please direct enquiries about this publication or requests for complimentary copies via:
Director
PBS Information Management Section
Pharmaceutical Policy Branch, MDP 900
Department of Health
GPO Box 9848 Canberra ACT 2601
E-mail PBS Stats
Facsimile: 02 6289 6970
Unless otherwise indicated this publication has been produced using data provided to the Department of Health by the Department of Human Services. The figures reported in this publication relate to the value (benefit) or volume of PBS prescriptions that have been processed by the Department of Human Services. They refer only to paid services processed from claims presented by approved suppliers. They do not include any adjustments made against claims, any manually paid claims or any benefits paid as a result of retrospective entitlement or refund of patient contributions.
PBS Expenditure includes the following patient categories:
- General - Ordinary
- General - Safety Net
- Concessional - Ordinary
- Concessional - Free Safety Net
- PBS Doctor's Bag
The patient category refers to the patient's eligibility status at the time of supply of the benefit. General patients hold a Medicare card, Concessional patients hold a Medicare card and one of the following cards from Centrelink:
- Pension Concession Card
- Commonwealth Seniors Health Card
- Health Care Card
There are two safety net thresholds – one for general patients and the other for concessional patients.
From 1 January 2015, the general patient safety net threshold was $1,453.90. When patients and/or their families reached this amount, they could apply for a Safety Net Concession Card and pay only $6.10 per prescription for the rest of the calendar year. The concessional safety net threshold was $366.00. Once patients and/or their families reached this amount, they could apply for a Safety Net Entitlement Card and receive items free of charge for the rest of the calendar year.
The Patient Contribution, Total Cost and Average Price amounts do not include brand or therapeutic premiums.
Caution should be exercised in referring to the breakdown by patient category in Table 20(a) on page 28 and Table 20(b) on page 32, because of a past problem in data supplied by the Department of Human Services whereby a number of General Safety Net scripts were wrongly allocated to Concessional Non-Safety Net. This problem has been fixed for 2008-09, but the 2006-07 and 2007-08 allocations of scripts and expenditure by patient category were inaccurate and not strictly comparable to the corresponding 2008-09 and later years’ numbers.
The Department of Health has taken every care to ensure the data supplied is accurate but does not warrant that the data is error free and does not accept any liability for errors or omissions in the data.